baltimore conference logo
  • MJHLS Brand Logo

© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Case-Based Peer Perspectives

Targeted Oncology presents Case-Based Peer Perspectives. In each video, expert physicians provide insight on managing oncology-based patient cases that highlight the use of novel agents in clinical practice.

A 73-Year-Old Woman With Differentiated Thyroid Cancer

Case Impressions: A 73-Year-Old Woman With DTC
Case Impressions: A 73-Year-Old Woman With DTC
Recommendations for Treating Patients With DTC
Recommendations for Treating Patients With DTC
Systemic Therapy for RAI-Refractory DTC
Systemic Therapy for RAI-Refractory DTC
Lenvatinib Data for RAI-Refractory DTC
Lenvatinib Data for RAI-Refractory DTC
Real-World Insight: Lenvatinib for RAI-Refractory DTC
Real-World Insight: Lenvatinib for RAI-Refractory DTC
Progress in Treating RAI-Refractory DTC
Progress in Treating RAI-Refractory DTC

A 77-Year-Old Woman with DLBCL

Case Overview: 77-Year-Old Woman With DLBCL
Case Overview: 77-Year-Old Woman With DLBCL
Approaching DLBCL: Risk Assessment and Prognosis
Approaching DLBCL: Risk Assessment and Prognosis
DLBCL: Cytogenetic Testing and Treatment Initiation
DLBCL: Cytogenetic Testing and Treatment Initiation
Frontline Treatment Approaches in DLBCL
Frontline Treatment Approaches in DLBCL
Current Treatment Approaches for R/R DLBCL
Current Treatment Approaches for R/R DLBCL
Implications for Treating R/R DLBCL With the L-MIND Regimen
Implications for Treating R/R DLBCL With the L-MIND Regimen
R/R DLBCL: Observations From the Re-MIND Study
R/R DLBCL: Observations From the Re-MIND Study
R/R DLBCL: Treating With Tafasitamab Plus Lenalidomide
R/R DLBCL: Treating With Tafasitamab Plus Lenalidomide
Progress Made in Treating R/R DLBCL
Progress Made in Treating R/R DLBCL

A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma

Presentation of a Patient With Diffuse Large B-Cell Lymphoma
Presentation of a Patient With Diffuse Large B-Cell Lymphoma
Initial Treatment of Diffuse Large B-Cell Lymphoma
Initial Treatment of Diffuse Large B-Cell Lymphoma
Results of the L-MIND Clinical Trial
Results of the L-MIND Clinical Trial
L-MIND Trial Regimen Overview
L-MIND Trial Regimen Overview
Novel Treatment Options in Diffuse Large B-Cell Lymphoma
Novel Treatment Options in Diffuse Large B-Cell Lymphoma

A 58-Year-Old Man With Advanced Renal Cell Carcinoma

Case Overview: 58-Year-Old Man With Advanced RCC
Case Overview: 58-Year-Old Man With Advanced RCC
Risk Stratification of Patients With Advanced RCC
Risk Stratification of Patients With Advanced RCC
Advanced RCC Treatment Selection
Advanced RCC Treatment Selection
Second-Line Treatment Options for Advanced RCC
Second-Line Treatment Options for Advanced RCC
Lenvatinib and Everolimus for Advanced RCC
Lenvatinib and Everolimus for Advanced RCC
Novel Therapies in Advanced RCC
Novel Therapies in Advanced RCC

A 71-Year-Old Woman with NTRK Gene Fusion Thyroid Cancer

A 71-Year-Old Woman With NTRK Gene Fusion Thyroid Cancer
A 71-Year-Old Woman With NTRK Gene Fusion Thyroid Cancer
NTRK Gene Fusion Thyroid Cancer: Incidence and Prognosis
NTRK Gene Fusion Thyroid Cancer: Incidence and Prognosis
Preferred Testing Methods and Treatment Options
Preferred Testing Methods and Treatment Options
LOXO-101 Trial Regimen Overview
LOXO-101 Trial Regimen Overview

A 73-Year-Old Male With Urothelial Carcinoma

73-Year-Old Man With Locally Advanced Urothelial Carcinoma
73-Year-Old Man With Locally Advanced Urothelial Carcinoma
Prognosis at Diagnosis of Urothelial Carcinoma
Prognosis at Diagnosis of Urothelial Carcinoma
Results of the JAVELIN Bladder 100 Trial
Results of the JAVELIN Bladder 100 Trial
Managing Patients on Avelumab for Urothelial Carcinoma
Managing Patients on Avelumab for Urothelial Carcinoma
PD-L1 Therapy for High-Risk Superficial Urothelial Carcinoma
PD-L1 Therapy for High-Risk Superficial Urothelial Carcinoma
Future Directions for Treating Urothelial Carcinoma
Future Directions for Treating Urothelial Carcinoma